CTL’s enzyme-linked immunospot (ELISPOT) assays are an effective readout system for cytokine-based immune monitoring and standardsation strategies.
In addition to its Clinical Laboratory Improvement Amendments (CLIA) certified, good laboratory practice (GLP) compliant laboratory operations in which the company performs ELISPOT assays for its clients, CTL specialises in developing and manufacturing image-based analysis, high-throughput 21 CFR Part 11 compliant instrumentation and software.
To facilitate the objective, scientifically-validated analysis of ELISPOT and FluoroSpot assays, CTL has developed the ImmunoSpot® line of visible light and fluorescence-enabled analysers and software, utilising well-established, published spot-counting principles.
The company’s scientists built and patented the first ELISPOT analyser at Case Western Reserve University in 1995, and CTL has since become a leading worldwide manufacturer of ELISPOT instrumentation and analysis software.
CTL’s ImmunoSpot® Analyzers are manufactured under an International Standards Organisation (ISO) 9001:2008 certified quality management system. With its expertise in both ELISPOT testing and instrumentation, CTL is uniquely qualified to be at the forefront of cytokine-based immune monitoring and standardisation strategies.